Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
48.69
+3.14 (6.89%)
At close: Nov 14, 2025, 4:00 PM EST
49.50
+0.81 (1.66%)
After-hours: Nov 14, 2025, 6:05 PM EST
Vaxcyte Employees
Vaxcyte had 414 employees as of December 31, 2024. The number of employees increased by 160 or 62.99% compared to the previous year.
Employees
414
Change (1Y)
160
Growth (1Y)
62.99%
Revenue / Employee
n/a
Profits / Employee
-$1,587,442
Market Cap
6.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PCVX News
- 11 days ago - Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewsWire
- 6 weeks ago - Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services - GlobeNewsWire
- 2 months ago - Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose - GlobeNewsWire
- 3 months ago - Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - GlobeNewsWire
- 6 months ago - Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - GlobeNewsWire
- 8 months ago - Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity - Seeking Alpha